 Ovarian Cancer: The importance of testing for genomic instability in addition to BRCA1/2 mutations in aOC

Dr. Vail is the director of the clinical molecular pathology laboratory at Cedars-Sinai Medical Center. The laboratory has a full suite of molecular diagnostic assays, encompassing viral, genetic and oncology testing. Dr. Vail’s academic focus is on the effective utilization of genomic biomarkers, especially those provided by NGS, in the clinical setting and provider outreach and education.

In this session, Dr. Eric Vail discusses the importance of genomic instability testing in advanced ovarian cancer patients. The session covers the clinical guidelines and recommendations for BRCA1/2 mutation testing and HRD status assessment through comprehensive genomic instability testing in ovarian cancer patients and its role in informing the use of PARPi therapy.